Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine)

This publication has 16 references indexed in Scilit:

• Hyperfractionated Irradiation with or without Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer
  New England Journal of Medicine, 1998
• Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA doublestrand breaks as measured by pulsed-field gel electrophoresis
  International Journal of Radiation Biology, 1998
• Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model
  Radiation Oncology Investigations, 1997
• Radiosensitizing Nucleosides
  JNCI Journal of the National Cancer Institute, 1996
• Five-Year Update of a Randomized Trial of Alternating Radiotherapy and Chemotherapy Compared With Radiotherapy Alone in Treatment of Unresectable Squamous Cell Carcinoma of the Head and Neck
  JNCI Journal of the National Cancer Institute, 1996
• A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
  Annals of Oncology, 1996
• Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine
  International Journal of Radiation Oncology*Biology*Physics, 1996
• 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines
  Biochemical Pharmacology, 1993
• 2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase
  Journal of Medicinal Chemistry, 1991
• An in vivo model for squamous cell carcinoma of the head and neck
  The Laryngoscope, 1985